The IL-23 inhibitor from AbbVie indicated for the treatment of moderate to severe plaque psoriasis (Ps) in adults who are candidates for systemic therapy or phototherapy and for adults with active psoriatic arthritis (PsA).1

Nothing less than the opportunity to reach their treatment goals

For your patients, that’s everything.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AND FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS1